CytomX Therapeutics (NASDAQ:CTMX) announces that collaboration partner AbbVie (NYSE:ABBV) has selected a second target under their 2016 agreement aimed at discovering and developing ProBody drug conjugates.
The action triggers a $10M milestone payment to CTMX.
The companies are also advancing a clinical-stage candidate, CX-2029, a Probody drug conjugate against a cell surface protein called CD71.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.